Inflammatory breast cancer in a previously treated case of breast cancer: a diagnostic dilemma for the clinician

BMJ Case Rep. 2016 Apr 8:2016:bcr2016214700. doi: 10.1136/bcr-2016-214700.

Abstract

Inflammatory breast cancer (IBC) is a relatively rare and aggressive subtype, accounting for nearly 2.5% of all diagnosed breast cancers worldwide. It is usually characterised by an acute onset, rapid clinical progression, poor prognosis and micrometastasis at the time of presentation. Prompt recognition of clinical symptoms and identification of warning signs are vital in diagnosing and appropriately treating a patient with IBC.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / therapy
  • Capecitabine / therapeutic use
  • Female
  • Humans
  • Inflammatory Breast Neoplasms / diagnosis*
  • Inflammatory Breast Neoplasms / drug therapy
  • Lapatinib
  • Middle Aged
  • Neoplasms, Second Primary / diagnosis*
  • Neoplasms, Second Primary / drug therapy*
  • Paclitaxel / therapeutic use
  • Prognosis
  • Quinazolines / therapeutic use

Substances

  • Quinazolines
  • Lapatinib
  • Capecitabine
  • Paclitaxel